Nordea Investment Management AB held its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 4,477 shares of the company’s stock at the end of the 2nd quarter. Nordea Investment Management AB’s holdings in IDEXX Laboratories were worth $723,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of IDEXX Laboratories by 4.0% during the second quarter. Vanguard Group Inc. now owns 9,264,579 shares of the company’s stock valued at $1,495,488,000 after acquiring an additional 354,024 shares in the last quarter. BlackRock Inc. grew its stake in shares of IDEXX Laboratories by 10.5% during the second quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after acquiring an additional 673,347 shares in the last quarter. State Street Corp grew its stake in shares of IDEXX Laboratories by 38.6% during the first quarter. State Street Corp now owns 3,911,739 shares of the company’s stock valued at $604,793,000 after acquiring an additional 1,089,880 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of IDEXX Laboratories by 59.1% during the first quarter. Renaissance Technologies LLC now owns 975,600 shares of the company’s stock valued at $150,838,000 after acquiring an additional 362,400 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of IDEXX Laboratories by 41.6% during the first quarter. Geode Capital Management LLC now owns 921,279 shares of the company’s stock valued at $142,250,000 after acquiring an additional 270,871 shares in the last quarter. Institutional investors own 87.64% of the company’s stock.

IDEXX Laboratories, Inc. (IDXX) opened at 158.97 on Monday. The firm has a market capitalization of $13.87 billion, a P/E ratio of 54.69 and a beta of 0.48. The company has a 50-day moving average price of $155.81 and a 200-day moving average price of $159.71. IDEXX Laboratories, Inc. has a 1-year low of $102.45 and a 1-year high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.10. The firm had revenue of $508.90 million during the quarter, compared to analyst estimates of $502.44 million. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The business’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.74 EPS. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post $3.18 earnings per share for the current fiscal year.

WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/09/idexx-laboratories-inc-idxx-position-maintained-by-nordea-investment-management-ab.html.

In related news, Director Lawrence D. Kingsley acquired 2,000 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was acquired at an average price of $151.76 per share, with a total value of $303,520.00. Following the completion of the transaction, the director now owns 3,344 shares of the company’s stock, valued at $507,485.44. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $155.22, for a total transaction of $2,793,960.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 151,734 shares of company stock valued at $23,436,626. Company insiders own 2.77% of the company’s stock.

IDXX has been the subject of several recent analyst reports. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Canaccord Genuity restated a “buy” rating and set a $180.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, June 13th. CL King upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 target price for the company in a research note on Friday, July 28th. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 target price for the company in a research note on Wednesday, July 19th. Finally, Stifel Nicolaus restated a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a research note on Friday, July 14th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. IDEXX Laboratories has an average rating of “Hold” and an average target price of $174.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Stock Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related stocks with our FREE daily email newsletter.